About Bausch & Lomb
Bausch & Lomb is a company based in Bridgewater (United States) founded in 1853 by John Jacob Bausch and Henry Lomb was acquired by Bausch Health in May 2013. The company has 13,500 employees as of December 31, 2024. Bausch & Lomb has completed 12 acquisitions, including AcuFocus, Doctor's Allergy Formula and ELIOS Vision. Bausch & Lomb operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
- Headquarter Bridgewater, United States
- Employees 13500 as on 31 Dec, 2024
- Founders John Jacob Bausch, Henry Lomb
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bausch + Lomb Corporation
-
Annual Revenue
$4.79 B (USD)15.56as on Dec 31, 2024
-
Net Profit
-$317 M (USD)-21.92as on Dec 31, 2024
-
EBITDA
$642 M (USD)9.56as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Bausch Health
& 2 more
-
Employee Count
13500
as on Dec 31, 2024
-
Investments & Acquisitions
AcuFocus
& 11 more
-
Acquired by
Bausch Health
(May 27, 2013)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bausch & Lomb
Bausch & Lomb is a publicly listed company on the NYSE with ticker symbol BLCO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Bausch & Lomb
Unlock access to complete
Funding Insights of Bausch & Lomb
Investors in Bausch & Lomb
Bausch & Lomb has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Bausch Health, IMRF and RGE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Therapeutics for multiple diseases including dermatology and neurology are developed.
|
Locked | Locked | Locked |
Investor details for Bausch Lomb
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bausch & Lomb
Bausch & Lomb has strategically engaged in corporate development activities, having acquired 12 companies. Notable acquisitions include AcuFocus, Doctor's Allergy Formula and ELIOS Vision.
Investment portfolio details for Bausch Lomb
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Excimer laser technology is applied to develop glaucoma therapy devices.
|
Locked | Locked | 2019 | Locked | |
|
Therapeutics for ophthalmological disorders, including glaucoma treatments, are developed.
|
Locked | Locked | 2015 | Locked | |
|
Diagnostics for ocular allergies are developed using regional allergen panels.
|
Locked | Locked | 2013 | Locked |
Complete acquisition details for Bausch Lomb
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Bausch Lomb
Detailed financials for Bausch Lomb
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bausch & Lomb Comparisons
Peer comparison for Bausch Lomb
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bausch & Lomb
Bausch & Lomb operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Bausch Lomb
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bausch & Lomb
Complete news archive for Bausch Lomb
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bausch & Lomb
Bausch & Lomb was founded in 1853 and raised its 1st funding round 162 years after it was founded.
Bausch & Lomb is headquartered in Bridgewater, United States. It is registered at Bridgewater, New Jersey, United States.
As of Dec 31, 2024, the latest employee count at Bausch & Lomb is 13,500.
Annual revenue of Bausch & Lomb is $4.79B as on Dec 31, 2024.
Bausch Lomb was founded in 1853 and is headquartered in Bridgewater, United States. Focus is placed on the ophthalmology sector, where pharmaceutical products, contact lenses, lens care items, eye care solutions, over-the-counter offerings, and surgical devices are developed and distributed. Operations encompass research, manufacturing, and global supply of these instruments and products to support eye health and vision correction needs.
Bausch & Lomb's top competitors include Merck, Roivant Sciences and AbbVie.
Yes, Bausch & Lomb is publicly traded on NYSE under the ticker symbol BLCO.
Bausch & Lomb has made 12 acquisitions, including AcuFocus, Doctor's Allergy Formula, and ELIOS Vision.
Bausch & Lomb has 3 investors. Key investors include Bausch Health, IMRF, and RGE.
The ticker symbol of Bausch & Lomb is BLCO on NYSE.